Ocular Therapeutix, Inc. (OCUL), a biopharmaceutical company focused on advancing retinal treatments, has granted inducement equity awards to a newly hired employee under its 2019 Inducement Stock Incentive Plan. The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) to facilitate the individual's acceptance of employment.
The inducement grants, effective as of January 13, 2025, include:A non-statutory stock option to purchase up to 95,600 shares of Ocular's common stock at the market price on the effective date.
A restricted stock unit or RSU award for 31,375 shares of common stock.
The stock options are set to vest over four years, with 25% vesting on January 13, 2026, and the remaining shares vesting in equal monthly installments.
The RSU award will vest over three years, with the first installment vesting on January 13, 2026, provided the individual remains employed by Ocular.
These inducement awards are part of Ocular's ongoing commitment to building a talented team to support the development of its innovative therapies.
Currently, OCUL is trading at $8.04 down 0.12%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.